Investigation Report on China’s Insulin Aspart Market, 2018-2022

$2,200$3,300

Description The rapid development of the Chinese economy in the past three decades has changed people’s dietary habits and reduced physical activities, which leads to an increasing incidence of obesity-related diseases. It is estimated that at the end of 2017, there were more than 100 million diabetic patients in China. The market size of diabetes drugs is also growing in China. On Dec. 26, 2001, Novo Nordisk announced that Insulin Aspart (trade name: NovoRapid), the first and only insulin analog that can be used with insulin pumps, was approved by … Continue reading Investigation Report on China’s Insulin Aspart Market, 2018-2022

Read more